OncoMatch/Clinical Trials/NCT07874542
Plasma DNA Methylation for Preoperative Classification of Renal Masses
Official title: METH-RENAL: A Prospective Clinical Development and Threshold-Setting Study of a Plasma DNA Methylation Classifier for the Preoperative Evaluation of Renal Masses
Is NCT07874542 recruiting? Yes, currently enrolling (Oct 2026).
METH-RENAL is a prospective observational diagnostic development and threshold-setting study in adults with a renal mass scheduled for partial or radical nephrectomy. Peripheral blood is collected before surgery, and postoperative histopathology serves as the reference standard. The study will develop and internally validate a plasma DNA methylation classifier and lock the final marker panel, algorithm, and positivity cut-off for a subsequent independent prospective multicenter validation study.
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Prior therapy
Cannot have received: systemic anticancer therapy
Systemic anticancer therapy ... of the index renal lesion before study blood collection.
Cannot have received: radiotherapy
radiotherapy ... of the index renal lesion before study blood collection.
Cannot have received: local ablation
local ablation ... of the index renal lesion before study blood collection.
Cannot have received: surgery/pathological sampling of the index renal lesion
surgery/pathological sampling of the index renal lesion before study blood collection.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07874542 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic anticancer therapy, radiotherapy, local ablation disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages